

4 August 2026

Oncology Gastro Cancer

1. How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction?

63

2. How many patients were treated in the past 3 months for gastric cancer (any stage) with:

• CAPOX (Capecitabine with Oxaliplatin)	6
• FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)	0
• Lonsurf (Trifluridine - tipiracil)	0
• Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	0
• Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	<5
• Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	0
• Zolbetuximab (Vyloy)	0
• Any other systemic anti-cancer therapy:	
OX Trast	<5
FLOT	<5
OMDG	<5
Pembro	<5
Ramac+Pac	<5
• Palliative care only	Not available
• Trastuzumab in combination with cisplatin and capecitabine (or 5-fluorouracil)	0
• Taxanes (e.g. docetaxel, paclitaxel)	0
• Irinotecan Chemotherapy	<5

4 August 2026

3. How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with:

• CAPOX (Capecitabine with Oxaliplatin)	6
• FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)	0
• Lonsurf (Trifluridine - tipiracil)	0
• Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	0
• Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	6
• Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	<5
• Zolbetuximab (Vyloy)	0
• Any other systemic anti-cancer therapy:	
CX	<5
FLOT	20
Nivolumab	<5
Nivolumab OMDG	<5
Pembro	<5
PTOX	<5
Weekly Pac/Carb XRT	<5
• Palliative care only	Not available
• Trastuzumab in combination with cisplatin and capecitabine (or 5-fluorouracil)	0
• Taxanes (e.g. docetaxel, paclitaxel)	<5
• Irinotecan Chemotherapy	<5

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.